Eli Lilly and Company
Rating
Strong Buy
High Conviction — Core Position
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
Dominant GLP-1 franchise with patent protection into the late 2030s, reinforced by a deep clinical pipeline and manufacturing scale advantages.
Eli Lilly's moat is anchored in scientific superiority and regulatory exclusivity that cannot be replicated quickly:
- Tirzepatide Efficacy Superiority: Mounjaro and Zepbound (tirzepatide) consistently outperform competing GLP-1 drugs in head-to-head efficacy data, with superior weight loss outcomes. This clinical evidence edge drives prescriber preference and formulary positioning that competitors must overcome with their own Phase 3 trial data — a multi-year barrier.
- Patent Wall Into the Late 2030s: Lilly's CEO has confirmed tirzepatide compound patent protection extends 'into the back half of the 2030s' in major markets, contrasting sharply with Novo Nordisk's semaglutide facing patent expiry in select markets today. This 10+ year runway allows Lilly to compound its GLP-1 franchise revenues without near-term generic erosion.
- Manufacturing Moat at Scale: Peptide manufacturing is extraordinarily complex; Lilly has invested billions into new manufacturing capacity globally. The expertise required to manufacture GLP-1 drugs at commercial scale — including sterile fill-finish and cold-chain logistics — represents a structural barrier that takes years for competitors to build.
Ten Moats Verdict
Lilly's core moat — patent-protected biologics with regulatory approval — is structurally immune to AI disruption, and AI drug discovery tools actually accelerate Lilly's pipeline advantage by compressing early-stage discovery timelines. The company is a net beneficiary of AI adoption, using it to identify novel targets and optimize clinical trials faster than underfunded competitors.
N/A — physicians prescribe drugs based on clinical evidence and patient outcomes, not UI familiarity; interface learning costs do not apply to pharmaceuticals.
Lilly's GLP-1 peptide synthesis, formulation IP, and cold-chain manufacturing know-how represent complex proprietary processes that competitors cannot decode from reverse engineering alone.
N/A — Lilly's competitive moat does not rely on controlling access to a public data source; not applicable to the pharmaceutical business model.
World-class endocrinologists, peptide chemists, and regulatory affairs specialists are scarce globally; Lilly's 140-year reputation and compensation attract the best pharma talent disproportionately.
N/A — pharmaceutical drugs are not sold in software-style bundles; individual drug approvals and prescriptions are the unit of sale.
Lilly holds decades of real-world clinical trial data for tirzepatide across thousands of patients — outcomes data that grows with every prescription and feeds future drug development and label expansions.
Mounjaro, Zepbound, and now Foundayo (FDA-approved April 1, 2026) each carry independent FDA approvals, EU/global regulatory clearances, GMP manufacturing certifications, and payer formulary placements — three interlocking regulatory moats that compound switching barriers across both injectable and oral GLP-1 channels.
Growing physician experience with tirzepatide creates a prescribing flywheel — more patient success stories build prescriber confidence and peer recommendations. Foundayo's April 2026 launch extends this network into the oral GLP-1 segment, deepening the flywheel across both injectable and pill modalities.
Mounjaro and Zepbound are embedded in major pharmacy benefit formularies, employer health plans, and Medicare Part D — removing them faces enormous patient, physician, and political resistance.
N/A — Lilly is a drug manufacturer, not a system-of-record platform; this moat type does not apply to the pharmaceutical industry.
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
Dominant GLP-1 franchise with patent protection into the late 2030s, reinforced by a deep clinical pipeline and manufacturing scale advantages.
Growth Score
Q1 2026 (Apr 30): Revenue $19.80B (+56% YoY), non-GAAP EPS $8.55 (+156%) — both crushing consensus ($17.6B / $6.85). Mounjaro $8.7B (+125% YoY), Zepbound $4.2B (+80%) — combined $12.8B in a single quarter. Management raised FY2026 guidance to $82–85B revenue (from $80–83B) and non-GAAP EPS $35.50–$37.00. FY2025 baseline: $65.18B (+44.7%). Foundayo (orforglipron oral GLP-1) FDA-approved April 1, 2026; analyst 2026 revenue est. $1.5–2.8B, priced at $299/mo self-pay or $25/mo with commercial insurance. Retatrutide TRIUMPH-4 Phase 3 confirmed 28.7% body weight loss / 71.2 lbs avg at high dose — seven additional Ph.3 readouts expected in 2026; GlobalData projects $15.6B in 2031 peak sales.
Valuation Score
At ~$988 — 18% below the $1,200 base case — LLY trades at a discount that compressed only modestly after the Q1 2026 blow-out (revenue +56%, EPS $8.55 vs $6.85 est, FY guidance raised to $82–85B / EPS $35.50–37.00). The remaining gap to base reflects oral GLP-1 competition risk and Medicare Part D negotiation overhang, not earnings concerns — the print confirmed accelerating fundamentals. Analyst consensus target moved up to ~$1,235 post-print, implying ~25% upside.
The GLP-1 Fortress
Eli Lilly's moat is anchored in scientific superiority and regulatory exclusivity that cannot be replicated quickly:
- Tirzepatide Efficacy Superiority: Mounjaro and Zepbound (tirzepatide) consistently outperform competing GLP-1 drugs in head-to-head efficacy data, with superior weight loss outcomes. This clinical evidence edge drives prescriber preference and formulary positioning that competitors must overcome with their own Phase 3 trial data — a multi-year barrier.
- Patent Wall Into the Late 2030s: Lilly's CEO has confirmed tirzepatide compound patent protection extends 'into the back half of the 2030s' in major markets, contrasting sharply with Novo Nordisk's semaglutide facing patent expiry in select markets today. This 10+ year runway allows Lilly to compound its GLP-1 franchise revenues without near-term generic erosion.
- Manufacturing Moat at Scale: Peptide manufacturing is extraordinarily complex; Lilly has invested billions into new manufacturing capacity globally. The expertise required to manufacture GLP-1 drugs at commercial scale — including sterile fill-finish and cold-chain logistics — represents a structural barrier that takes years for competitors to build.
Ten Moats Verdict
Lilly's core moat — patent-protected biologics with regulatory approval — is structurally immune to AI disruption, and AI drug discovery tools actually accelerate Lilly's pipeline advantage by compressing early-stage discovery timelines. The company is a net beneficiary of AI adoption, using it to identify novel targets and optimize clinical trials faster than underfunded competitors.
N/A — physicians prescribe drugs based on clinical evidence and patient outcomes, not UI familiarity; interface learning costs do not apply to pharmaceuticals.
Lilly's GLP-1 peptide synthesis, formulation IP, and cold-chain manufacturing know-how represent complex proprietary processes that competitors cannot decode from reverse engineering alone.
N/A — Lilly's competitive moat does not rely on controlling access to a public data source; not applicable to the pharmaceutical business model.
World-class endocrinologists, peptide chemists, and regulatory affairs specialists are scarce globally; Lilly's 140-year reputation and compensation attract the best pharma talent disproportionately.
N/A — pharmaceutical drugs are not sold in software-style bundles; individual drug approvals and prescriptions are the unit of sale.
Lilly holds decades of real-world clinical trial data for tirzepatide across thousands of patients — outcomes data that grows with every prescription and feeds future drug development and label expansions.
Mounjaro, Zepbound, and now Foundayo (FDA-approved April 1, 2026) each carry independent FDA approvals, EU/global regulatory clearances, GMP manufacturing certifications, and payer formulary placements — three interlocking regulatory moats that compound switching barriers across both injectable and oral GLP-1 channels.
Growing physician experience with tirzepatide creates a prescribing flywheel — more patient success stories build prescriber confidence and peer recommendations. Foundayo's April 2026 launch extends this network into the oral GLP-1 segment, deepening the flywheel across both injectable and pill modalities.
Mounjaro and Zepbound are embedded in major pharmacy benefit formularies, employer health plans, and Medicare Part D — removing them faces enormous patient, physician, and political resistance.
N/A — Lilly is a drug manufacturer, not a system-of-record platform; this moat type does not apply to the pharmaceutical industry.
Growth Analysis
Growth Drivers
Key Risk
If Novo Nordisk's oral Wegovy pill sustains a >2:1 prescription lead over Foundayo through Q3 2026 AND Structure Therapeutics' aleniglipron Phase 3 outperforms orforglipron in 2027, LLY's oral GLP-1 market share falls below 25% and analyst 2028 EPS estimates decline 15%+
Score Derivation
Base 90 (30%+ CAGR) + 5 Q1 2026 confirmation (revenue +56% YoY actual, FY guidance raised to $82–85B) + 5 retatrutide next-gen catalyst (TRIUMPH-4 Phase 3 confirmed 28.7%/71.2 lbs; 7 more 2026 readouts) − 5 oral competition headwind (Wegovy pill leads early Foundayo Rx; Structure Therapeutics aleniglipron Phase 2) − 5 pricing risk (Medicare Part D negotiation risk) = 90
Price Scenarios (12–24 Months)
Valuation Multiples
| Trailing P/E (GAAP) | ~41× |
| Forward P/E (NTM) | ~27× |
| PEG Ratio | ~0.6× |
| Price / Sales (NTM) | ~10× |
| Price / FCF | ~33× |
Forward P/E compressed from ~33× to ~27× post-print as guidance was raised faster than the share price moved — PEG fell to ~0.6×, deepening the relative discount to large-cap pharma peers (~45×). The 41× trailing vs 27× forward gap confirms still-accelerating earnings, not multiple expansion. The Q1 print resolved the 'will guidance hold' overhang; the market now needs evidence Foundayo can close the script gap with Wegovy oral and that retatrutide's remaining 2026 readouts hold the TRIUMPH-4 bar.
Approximate figures as of May 2026.
Where We Are vs Targets
Loading live price…
Foundayo adoption disappoints as Wegovy pill leads on scripts, pricing pressure erodes net revenue, and a retatrutide late Phase 3 setback removes the next-gen premium.
- Novo Nordisk's oral Wegovy pill sustains a >2:1 prescription lead over Foundayo through 2026, capturing 30%+ of new oral GLP-1 prescriptions; Structure Therapeutics' aleniglipron Phase 3 outperforms Foundayo in 2027, fragmenting LLY's oral market share below 20%
- U.S. Medicare/Medicaid Part D GLP-1 net pricing negotiations cut realised prices by 25%+ before 2028, compressing revenue growth below 15% and pushing FY2027 revenue to ~$90B vs. consensus $110B+
- Retatrutide late Phase 3 readouts fail to maintain the TRIUMPH-4 superiority across all indications — settling at ~20% mean weight loss — eliminating the 'best-in-class next-gen' premium and leaving LLY without a differentiated asset beyond Zepbound
Foundayo gains adoption momentum closing the Wegovy script gap by Q3 2026, retatrutide's remaining Phase 3 readouts confirm superiority, and FY2026 revenue closes at the high end of guidance.
- Foundayo narrows the Wegovy pill prescription gap to <1.5:1 by Q3 2026 as patients and prescribers favour its no food/water restriction dosing; LLY secures telehealth distribution with Hims or a rival platform, capturing 25%+ of new oral GLP-1 Rx
- Retatrutide's remaining 2026 Phase 3 readouts maintain 22%+ mean body weight loss across indications, with FDA submission by end of 2026 — establishing LLY as the only company with best-in-class oral and injectable next-gen GLP-1s
- Kisunla (donanemab) exceeds $500M FY2026 revenue on growing Alzheimer's formulary access, and FY2026 revenue closes at the high end of $80–83B guidance with non-GAAP EPS ~$35
Retatrutide becomes the best-in-class weight-loss drug confirmed by Phase 3 data, Foundayo accelerates to mainstream oral adoption, and Kisunla reaches blockbuster scale.
- Retatrutide Phase 3 breadth (TRIUMPH-4 confirmed 28.7%/71.2 lbs avg) across all 2026 readouts leads to FDA approval by mid-2027; GlobalData $15.6B 2031 sales projection realised, generating >$10B revenue by 2029
- Foundayo penetrates 30%+ of the oral obesity market within 3 years of launch, as no food/water restriction advantage drives patient preference over Wegovy pill — doubling the addressable patient pool vs. injection-only therapies
- Kisunla (donanemab) reaches $3B+ annual revenue by 2028 as Alzheimer's diagnosis rates improve and reimbursement expands globally, reducing GLP-1 revenue concentration below 60%